Medical devices, healthcare technology and the business of care
PMA approval · P130021

MEDTRONIC COREVALVE SYSTEM

Medtronic, Inc. · Decision date Jan 17, 2014

FDA DECISIONP130021

What did the FDA approve?

FDA records P130021 as an original PMA application. The recorded decision is approval, dated Jan 17, 2014.

FDA approval order statement

Approval for the Medtronic CoreValve System. This device is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis (aortic valve area ? 0.8 cm2, a mean aortic valve gradient of > 40 mmHg, or a peak aortic-jet velocity of > 4.0 m/s) and with native aortic annulus diameters between 18 and 29 mm who are judged by a heart team, including a cardiac surgeon, to be at extreme risk or inoperable for open surgical therapy (predicted risk of operative mortality and/or serious irreversible morbidity ? 50% at 30 days).
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Jan 17, 2014

FDA source record

Regulatory record facts

Identifier
P130021
Regulatory pathway
Premarket approval application
Product code
NPT
Decision code
APPR
Decision date
Jan 17, 2014
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Aortic valve, prosthesis, percutaneously delivered.

Product code
NPT
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P130021 received

    Application receipt date recorded by FDA.

  2. P130021 · FDA decision

    APPR

  3. P130021/S188 · Related supplement

    Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti

Timeline entries are records held by MedtechLedger for P130021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130021

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementNov 7, 2026FDA

Explore the linked device profile

Other records with product code NPT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
710 Medtronic Pkwy., Miinneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records